<DOC>
	<DOCNO>NCT01409343</DOCNO>
	<brief_summary>This prospective , open label , multicenter study evaluate safety , tolerability pharmacokinetics TrasGEX™ intravenous administration patient HER-2 positive cancer . The effect TrasGEX™ development anti-drug antibody tumour response also evaluate .</brief_summary>
	<brief_title>TrasGEX™ : Dose Escalation Study</brief_title>
	<detailed_description />
	<criteria>Main 1 . Signed write informed consent grant prior initiation studyspecific procedure ; 2 . Male female patient ≥18 year age ; 3 . ERBB2 ( HER2 ) gene amplification ERBB2 overexpression 4 . Histologically cytologically confirm cancer , either locally advanced metastatic ; 5 . No antitumor therapy proven benefit available study enrollment ; 6 . Life expectancy &gt; =3 month ; 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) &lt; =2 ; 8 . Male female patient childproducing potential must agree use contraceptive measure oral contraception study 28 day last dose TrasGEX™ ; 9 . Female patient childbearing potential must negative serum pregnancy test within 7 day prior first dose TrasGEX™ ; Main 1 . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within 4 week first dose TrasGEX™ ; 2 . Major surgery within four week first dose TrasGEX™ ; 3 . Newly diagnose brain metastasis , metastasis document stable &lt; 3 month , metastasis systemic corticosteroid require ; 4 . History allergic reaction attribute compound similar chemical biologic composition TrasGEX™ ; 5 . History myocardial infarction within 12 month administration first dose TrasGEX™ ; 6 . History congestive heart failure define Class II IV per New York Heart Association classification within 12 month administration first dose TrasGEX™ ; 7 . Left ventricular ejection fraction &lt; 50 % ; 8 . Previous malignancy current diagnosis within 5 year first dose TrasGEX™ ; 9 . Pregnancy lactation ; 10 . Concurrent uncontrolled significant illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>advanced solid cancer</keyword>
	<keyword>metastatic solid cancer</keyword>
</DOC>